If you have unresectable non-small cell lung cancer, your doctor may recommend radiation, chemotherapy, and other therapies to treat the cancer. Plus procedures to help with your symptoms and side ...

Iovance investors got great news in February when the Food and Drug Administration approved Amtagvi (lifileucel), the company ...

The approval of AstraZeneca’s and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for adults with unresectable or metastatic HER2-positive solid tumors adds to the drug's approved indications in ...

Authors primarily from the West German Cancer Center in Essen, Germany, presented findings from a phase 2 study (NCT04205552) ...

Following the earlier results, the US Food and Drug Administration (FDA) gave accelerated approval to Keytruda in combination ...

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO -- A third of patients with previously treated ...

Tislelizumab is greenlit as a first-line treatment in combination with certain drugs in non-small cell lung cancer.

Opens in a new tab or window The FDA granted tumor-agnostic accelerated approval to trastuzumab deruxtecan (Enhertu) for previously treated unresectable or metastatic HER2-positive ...

Treatment with Dato-DXd reduced the risk of disease progression or death by 37% compared with chemotherapy. The Food and Drug Administration (FDA) has accepted the Biologics License Application ...

Continued approval of this tumor agnostic indication is contingent upon verification of clinical benefit in a confirmatory trial. The Food and Drug Administration (FDA) has granted accelerated ...

So far, toripalimab has been approved for marketing in the Chinese mainland and the US. Several NDAs are currently under regulatory review in the European Union, UK, Australia, Singapore, Malaysia and ...